Ingle JN - Search Results

1

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN. Goetz MP, et al. Among authors: ingle jn. Breast Cancer Res Treat. 2007 Jan;101(1):113-21. doi: 10.1007/s10549-006-9428-0. Epub 2006 Nov 18. Breast Cancer Res Treat. 2007. PMID: 17115111

2

HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.

Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, Wold LE. Perez EA, et al. Among authors: ingle jn. Mayo Clin Proc. 2002 Feb;77(2):148-54. doi: 10.4065/77.2.148. Mayo Clin Proc. 2002. PMID: 11838648

3

Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.

Reinholz GG, Getz B, Sanders ES, Karpeisky MY, Padyukova NSh, Mikhailov SN, Ingle JN, Spelsberg TC. Reinholz GG, et al. Among authors: ingle jn. Breast Cancer Res Treat. 2002 Feb;71(3):257-68. doi: 10.1023/a:1014418017382. Breast Cancer Res Treat. 2002. PMID: 12002344

4

Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy.

Witzig TE, Bossy B, Kimlinger T, Roche PC, Ingle JN, Grant C, Donohue J, Suman VJ, Harrington D, Torre-Bueno J, Bauer KD. Witzig TE, et al. Among authors: ingle jn. Clin Cancer Res. 2002 May;8(5):1085-91. Clin Cancer Res. 2002. PMID: 12006523

5

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.

Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA. Roche PC, et al. Among authors: ingle jn. J Natl Cancer Inst. 2002 Jun 5;94(11):855-7. doi: 10.1093/jnci/94.11.855. J Natl Cancer Inst. 2002. PMID: 12048274

6

TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors.

Sinclair CS, Adem C, Naderi A, Soderberg CL, Johnson M, Wu K, Wadum L, Couch VL, Sellers TA, Schaid D, Slezak J, Fredericksen Z, Ingle JN, Hartmann L, Jenkins RB, Couch FJ. Sinclair CS, et al. Among authors: ingle jn. Cancer Res. 2002 Jul 1;62(13):3587-91. Cancer Res. 2002. PMID: 12097257

7

Estrogen as therapy for breast cancer.

Ingle JN. Ingle JN. Breast Cancer Res. 2002;4(4):133-6. doi: 10.1186/bcr436. Epub 2002 May 15. Breast Cancer Res. 2002. PMID: 12100736 Free PMC article.

8

Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR.

Reinholz MM, Iturria SJ, Ingle JN, Roche PC. Reinholz MM, et al. Among authors: ingle jn. Breast Cancer Res Treat. 2002 Jun;74(3):255-69. doi: 10.1023/a:1016339120506. Breast Cancer Res Treat. 2002. PMID: 12206515

9

Sequencing of hormonal therapy in breast cancer.

Ingle JN. Ingle JN. Breast J. 2002 Nov-Dec;8(6):332-7. doi: 10.1046/j.1524-4741.2002.08602.x. Breast J. 2002. PMID: 12390355 Review.

10

Adjuvant endocrine therapy in postmenopausal breast cancer.

Ingle JN. Ingle JN. Clin Cancer Res. 2003 Jan;9(1 Pt 2):480S-5S. Clin Cancer Res. 2003. PMID: 12538504 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

424 results

Search Page